Indian Benchmark indices were in the green in a choppy market led by gains in metals and IT stocks. Gland Pharma makes stock markets debut at 14 percent premium over issue price.

Shares of Gland Pharma made a stellar debut on the Exchanges as they listed at Rs 1,710, a 14 percent premium against the issue price of Rs 1,500 per share on the National Stock Exchange (NSE) on Friday. On the BSE, the stock opened at Rs 1,701, 13 percent higher against its issue price. It moved higher to Rs 1,740 later and was trading at Rs 1,728, 15 percent above its issue price at 10:01 am. A combined 3.2 million shares have changed hands on the counter so far. In comparison, the S&P BSE Sensex was up 0.37 percent at 43,760 points.

The Rs 6,480-cr IPO of Gland Pharma managed to sail through solely on the back of institutional investor demand. The qualified institutional investors' portion was oversubscribed by 6.4 times. The retail and non-institutional investor portions were subscribed just 24 percent and 51 percent. The price band was set at Rs 1,490-1,500 per share. Gland Pharma is one of the largest and fastest-growing injectable-focused B2B companies, with a global footprint across 60 countries, including the US, Europe, Canada, Australia, India, and other markets.

Asian markets were mixed in early Friday deals. South Korea's Kospi was up 0.1 percent, Japan's Nikkei slipped 0.4 percent, while Hong Kong's Hang Seng added 0.3 percent.

SEBI demands Rs 62,600 cr from Sahara in Supreme Court petition

Railways completes RFQ evaluation for PPP in Passenger Train Operations Project

Titan Company shines in jewelry sales growth during Diwali